ew rise expect
analysi frame think possibl
rise confid us tavr market drive stock expect higher ew
significantli outperform univers past month ytd driven
superior low-risk tavr clinic trial result march strong perform
compani tavr busi feedback market clinician
remain posit street estim creep higher recent week result
debat among investor concern among sharehold whether
compani exceed street expect tavr sale estim
around mil current reiter outperform rate ew rais
target price
revis center-driven tavr model show upsid mil
updat quarterli model ew tavr revenu includ
product new exist center adjust normal season
base analysi see potenti upsid estim consensu rang
mil reflect y/i growth
what new weve updat center-bas bottoms-up analysi tavr
sale ew take account product new exist center
estim current around center total
end last year high level estim approxim larger
center perform averag tavr procedur annual around small-
mid-siz center perform averag around procedur per year
valuat target price base ev/ebitda multipl
previous ntm ebitda estim one year forward
bil risk includ key product approv delay unexpect chang
coverag tavr greater-than-expect share loss potenti new litig
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
global manufactur provid
medic devic equip structur valvular heart diseas
critic care
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv growth
high-growth segment grow growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base emerg segment deliv growth
high-growth segment grow growth grow
 close
expect strength volum continu temper season
anecdot feedback clinician tct strength ew beat set
expect higher recent week revis bottom-up analysi project
rang quarterli tavr sale includ increment potenti upsid higher
volum carri off-set degre season histor
caus grow slightli less ew tavr busi consist
compani strongest quarter tavr indic up-arrow chart
rang around imput like us tavr estim base bottom-up
center-driven model driven prospect center perform either
less tavr procedur per quarter repres plu minu mil per quarter
next three quarter continu view estim tavr beatabl ew
part due strong beat anecdot posit comment clinician tct
point one difficulti conduct effect survey check tavr
market much growth market driven smaller mid-siz
center versu larger well-known center account growth
see figur reason continu calibr feedback check
larger center understand gener grow market growth rate
small mid-siz center grow market forese futur
figur center-driven analysi ew tavr project
figur acceler growth driven small-mid center
 tavr sale mm ew tavr sale mm sale larg centerssal small/mid centerslarg charl martineau pm univers toronto octob
rais target price
continu view ew stock perform driven primarili posit neg
swing consensu expect long-term tavr market result
formul rel straightforward two-stag method construct valuat case
stock support new price target first evalu
ev/ebitda averag multipl rel ew trade roughli averag
year multipl forward ebitda pleas see figur base
current ev/ebitda multipl would equat
baselin ev/evitda multipl ew baselin valuat multipl refer
averag valuat market discount stock base current consensu
estim long-term tavr market street estim risen bil
bil project bil given price target current base
bil ntm ebitda project one year would result baselin valu
per share publish previous estim bil
increas consensu long-term tavr market project equat per share
ew see figur given consensu expect tavr market
increas bil would estim get us base line valu
also expect consensu estim long-term tavr market rise
anoth bil next twelv month driven rise confid potenti growth
relat low-risk indic tavr project drive stock
line new target
figur ew histor ev/ebitda rel multipl
figur sensit ew valuat lt tavr market expect
vs estim mm except per share data lt tavr market project tavr market market share project ebit ebitda mult target /share impact compani report credit suiss estiamt charl martineau pm univers toronto octob
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
